Trial Profile
A Phase II Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of Herceptin Administered Subcutaneously in Combination With Paclitaxel in Women With HER2 Overexpressing Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 03 Feb 2010 Actual end date (November 2001) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2007 New trial record.